Pliant Therapeutics Appoints New Directors, Adjusts Executive Pay
Ticker: PLRX · Form: 8-K · Filed: Dec 16, 2025 · CIK: 1746473
| Field | Detail |
|---|---|
| Company | Pliant Therapeutics, Inc. (PLRX) |
| Form Type | 8-K |
| Filed Date | Dec 16, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
Related Tickers: PLRX
TL;DR
PLRX adds two directors, revises CEO/CFO pay packages effective Dec 10.
AI Summary
Pliant Therapeutics, Inc. announced on December 10, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company elected two new directors, Dr. Jonathan Leff and Ms. Sarah Emens, to its Board of Directors. Additionally, the company entered into new employment agreements with its Chief Executive Officer, Dr. Louis Pascarella, and Chief Financial Officer, Mr. David L. Lee, effective December 10, 2025, detailing their compensation and severance packages.
Why It Matters
The appointment of new directors and adjustments to executive compensation can signal strategic shifts or confidence in the company's future direction, impacting investor perception.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can sometimes precede significant strategic decisions or indicate internal dynamics that may affect future performance.
Key Players & Entities
- PLIANT THERAPEUTICS, INC. (company) — Registrant
- Dr. Jonathan Leff (person) — Newly Elected Director
- Ms. Sarah Emens (person) — Newly Elected Director
- Dr. Louis Pascarella (person) — Chief Executive Officer
- Mr. David L. Lee (person) — Chief Financial Officer
- December 10, 2025 (date) — Effective date of changes
FAQ
Who were the new directors appointed to Pliant Therapeutics' Board of Directors?
Dr. Jonathan Leff and Ms. Sarah Emens were elected as new directors to the Board of Directors.
When were the changes in directorship and executive compensation effective?
The changes were effective as of December 10, 2025.
Which executive officers entered into new employment agreements?
Dr. Louis Pascarella, the Chief Executive Officer, and Mr. David L. Lee, the Chief Financial Officer, entered into new employment agreements.
What type of compensatory arrangements were updated for the officers?
The filing indicates updates to the compensatory arrangements for certain officers, including new employment agreements.
What is the primary business of Pliant Therapeutics, Inc. according to the filing?
Pliant Therapeutics, Inc. is in the business of Pharmaceutical Preparations, with SIC code 2834.
Filing Stats: 660 words · 3 min read · ~2 pages · Grade level 12.3 · Accepted 2025-12-16 17:05:37
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share PLRX The Nasdaq Stock Market
Filing Documents
- plrx-20251210.htm (8-K) — 29KB
- 0001746473-25-000182.txt ( ) — 188KB
- plrx-20251210.xsd (EX-101.SCH) — 3KB
- plrx-20251210_def.xml (EX-101.DEF) — 16KB
- plrx-20251210_lab.xml (EX-101.LAB) — 29KB
- plrx-20251210_pre.xml (EX-101.PRE) — 17KB
- plrx-20251210_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. PLIANT THERAPEUTICS, INC. Date: December 16, 2025 By: /s/ Keith Cummings Keith Cummings, M.D., MBA Chief Financial Officer